Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.

Human pathology - 1 Sept 2021

Lawson Barrett C, Yang Richard K, Euscher Elizabeth D, Ramalingam Preetha, Malpica Anais

Abstract excerpt

Molecular findings in ovarian, fallopian tube, and peritoneal high-grade serous carcinoma (HGSCa) are emerging as potential prognostic indicators. The chemotherapy response score (CRS) has been proposed as a histologic-based prognostic factor in patients with HGSCa treated with neoadjuvant chemotherapy (NACT). No study details the relationship between the mutational landscape of HGSCa and the CRS. This study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystadenocarcinoma, Serous

Share to Fallopian Tube Neoplasms

Share to Neoadjuvant Therapy

Share to Ovarian Neoplasms

Share to Peritoneal Neoplasms

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 34153306
DOI: 10.1016/j.humpath.2021.06.003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma.PMID 34153306Read ↗

Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.Semantic proximity Read ↗

TP53 mutations in high grade serous ovarian cancer and impact on clinical outcomes: a comparison of next generation sequencing and bioinformatics analysesSemantic proximity Read ↗

Targeted DNA sequencing of high-grade serous ovarian carcinoma reveals association of TP53 mutations with platinum resistance when combined with gene expression.Semantic proximity Read ↗

Molecular Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Identification of Novel Somatic TP53 Mutations in Patients with High-Grade Serous Ovarian Cancer (HGSOC) Using Next-Generation Sequencing (NGS)Semantic proximity Read ↗

Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.Semantic proximity Read ↗

Impact of Neoadjuvant Chemotherapy on Somatic Mutation Status in High-grade Serous Ovarian CarcinomaSemantic proximity Read ↗

Multiomic characterisation of high grade serous ovarian carcinoma enables high resolution patient stratificationSemantic proximity Read ↗

Critical molecular abnormalities in high-grade serous carcinoma of the ovary.Semantic proximity Read ↗

Clinicogenomic Landscape of Histologic Subtypes in Ovarian Cancer: Real-World Evidence From a Japanese Nationwide Cohort.Semantic proximity Read ↗

Classification of High-Grade Serous Ovarian Carcinoma by Epithelial-to-Mesenchymal Transition Signature and Homologous Recombination Repair Genes.Semantic proximity Read ↗

Clinical relevance of gain-of-function mutations of p53 in high-grade serous ovarian carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.